COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,788 Articles (22,523 medRxiv, 8,265 bioRxiv)

Most recent first Previous |  Page 690: Articles 6891-6900  | Next

Epidemiological characteristics and transmission dynamics of the outbreak caused by the SARS-CoV-2 Omicron variant in Shanghai, China: a descriptive study
Chen, Z., Deng, X., Fang, L., Sun, K., Wu, Y., Che, T., Zou, J., Cai, J., Liu, H., Wang, Y., Wang, T., Tian, Y., Zheng, N., Yan, X., Sun, R., Xu, X., Zhou, X., Ge, S., Liang, Y., Yi, L., Yang, J., Zhang, J., Ajelli, M., Yu, H.
10.1101/2022.06.11.22276273 — Posted: 2022-06-18
How do Urban Factors Control the Severity of COVID-19?
Roxon, J., Dumont, M.-S., Vilain, E., Pellenq, R.
10.1101/2022.06.17.22276576 — Posted: 2022-06-18
Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients During the Omicron Phase
Aggarwal, N., Beaty, L. E., Bennett, T. D., Carlson, N. E., Ginde, A. A.
10.1101/2022.06.17.22276575 — Posted: 2022-06-18
SARS-CoV-2 infection-induced immunity and the duration of viral shedding: results from a Nicaraguan household cohort study
Maier, H. E., Plazaola, M., Lopez, R., Sanchez, N., Saborio, S., Ojeda, S., Barilla, C., Kuan, G., Balmaseda, A., Gordon, A.
10.1101/2022.06.17.22276565 — Posted: 2022-06-18
COVFlow: virus phylodynamics analyses from selected SARS-CoV-2 sequences
Danesh, G., Boennec, C., Verdurme, L., Roussel, M., Trombert, S., Visseaux, B., Haim-Boukobza, S., Alizon, S.
10.1101/2022.06.17.496544 — Posted: 2022-06-17
Electrostatic features for the Receptor binding domain of SARS-COV-2 wildtype and its variants. Compass to the severity of the future variants with the charge rule.
Barroso da Silva, F. L., Giron, C. C., Laaksonen, A.
10.1101/2022.06.16.496458 — Posted: 2022-06-17
Home-use Photobiomodulation Device Treatment Outcomes for COVID-19
Lim, L., Hosseinkhah, N., Buskirk, M. V., Berk, A., Loheswaran, G., Abbaspour, Z., Smith, A., Karimpoor, M., Au, Y. N., Ho, K. F., Pushparaj, A., Zahavi, M., White, A., Rubine, J., Zidel, B., Henderson, C., Clayton, R. G., Tingley, D. R., Karimpoor, M., Miller, D. J., Hamblin, M. R.
10.1101/2022.06.16.22276503 — Posted: 2022-06-17
The prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up
Adriaenssens, N., Scholtes, B., Bruyndonckx, R., Van Ngoc, P., Verbakel, J. Y., De Sutter, A., Heytens, S., Van den Bruel, A., Desombere, I., Van Damme, P., Goossens, H., Buret, L., Duysburgh, E., Coenen, S.
10.1101/2022.06.17.22276478 — Posted: 2022-06-17
COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
Epling, B. P., Rocco, J. M., Boswell, K. L., Laidlaw, E., Galindo, F., Kellogg, A., Das, S., Roder, A., Ghedin, E., Kreitman, A., Dewar, R. L., Kelly, S. E. M., Kalish, H., Rehman, T., Highbarger, J., Rupert, A., Kocher, G., Holbrook, M. R., Lisco, A., Manion, M., Koup, R. A., Sereti, I.
10.1101/2022.06.16.22276392 — Posted: 2022-06-17
Immunogenicity following two doses of BBIBP-CorV vaccine and a third booster dose with viral vector and mRNA COVID-19 vaccines against delta and omicron variants in prime immunized adults with two doses of BBIBP-CorV vaccine
Chansaenroj, J., Suntronwong, N., Kanokudom, S., Assawakosri, S., Yorsaeng, R., Vichaiwattana, P., Klinfueng, S., Wongsrisang, L., Srimuan, D., Thatsanatorn, T., Thongmee, T., Auphimai, C., Nilyanimit, P., Wanlapakorn, N., Sudhinaraset, N., Poovorawan, y.
10.1101/2022.06.16.22276480 — Posted: 2022-06-17

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).